Drugmaker Viatris Inc. is considering a potential sale of its consumer health assets in Europe in a deal that could be valued at over 3 billion euros ($2.9 billion), Bloomberg News reported on Tuesday, citing people familiar with the matter.

The U.S. Supreme Court on Monday declined to hear Biogen Inc’s (BIIB.O) bid to win reinstatement of a patent on the company’s blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc. subsidiary (VTRS.O) Mylan Pharmaceuticals Inc.

On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.

Biogen Inc. on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer’s disease drug being developed with Eisai Co. Ltd. and promising to draw lessons from the setbacks to its treatment Aduhelm.